Nurix Therapeutics (NRIX) Price & Analysis

Compare

549 Followers

NRIX Stock Chart & Stats

$16.55

$0.42(2.22%)

At close: Jan 08 4:00 PM EST

$16.55

$0.42(2.22%)

Day’s Range― - ―

52-Week Range$8.18 - $22.50

Previous CloseN/A

Volume302.00K

Average Volume (3M)1.11M

Market Cap

$1.70B

Enterprise Value$1.24B

Total Cash (Recent Filing)$592.94M

Total Debt (Recent Filing)$55.73M

Price to Earnings (P/E)―

Beta1.48

Next Earnings

Apr 14, 2026

EPS Estimate

-0.77

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.82

Shares Outstanding102,843,010

10 Day Avg. Volume1,208,865

30 Day Avg. Volume1,105,864

Financial Highlights & Ratios

PEG Ratio-0.94

Price to Book (P/B)2.72

Price to Sales (P/S)17.45

P/FCF Ratio-5.56

Enterprise Value/Market Cap0.73

Enterprise Value/Revenue14.81

Enterprise Value/Gross Profit-16.95

Enterprise Value/Ebitda-4.84

Forecast

1Y Price Target

$30.50

Price Target Upside84.29% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

EPS Forecast (FY)-3.12

Revenue Forecast (FY)$57.76M

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy And TolerabilityDurable, deepening responses and an improved tolerability profile in heavily pretreated chronic lymphocytic leukemia patients support a stronger commercial positioning if confirmatory data are consistent.

Partnerships And Pipeline OptionalityAdvancing partnered programs and multiple degraders entering clinical testing expand future therapeutic options and create several potential upside catalysts beyond the lead asset.

Regulatory Pathway And Pivotal TrialInitiation of a pivotal head-to-head study combined with pursuit of an accelerated approval pathway could materially increase the likelihood of earlier market authorization for the lead candidate and lift investor expectations.

Bears Say

Competitive Pressure And Disclosure-driven VolatilityCompetitor disclosures about similar degrader programs in related indications heighten competitive pressure and increase the potential for market- or data-driven stock swings.

Execution And Development RiskDependence on multiple pivotal trials and sequential clinical readouts creates execution risk and could drive significant stock volatility if results are delayed or unfavorable.

Regulatory Approval And Market Uptake RiskFailure to obtain regulatory approvals or weaker-than-expected commercial uptake would materially reduce the company’s projected revenue potential and harm valuation.

Nurix Therapeutics News

3 ‘Strong Buy’ Biotech Stocks to Buy Now, 1/29/2026, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

9d ago

CRVS

NRIX

Nurix Therapeutics price target raised to $35 from $33 at Stifel

Stifel raised the firm’s price target on Nurix Therapeutics (NRIX) to $35 from $33 and keeps a Buy...

9d ago

NRIX

Nurix Therapeutics price target lowered to $29 from $30 at Wells Fargo

Wells Fargo analyst Derek Archila lowered the firm’s price target on Nurix Therapeutics (NRIX) to $29 from $30...

9d ago

NRIX

Nurix Therapeutics price target raised to $35 from $32 at Piper Sandler

Piper Sandler raised the firm’s price target on Nurix Therapeutics (NRIX) to $35 from $32 and keeps an...

9d ago

NRIX

Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Nurix Therapeutics (NRIX) to $32 from $31 and keeps a...

9d ago

NRIX

Nurix Therapeutics reports Q4 EPS (82c), consensus (92c)

Reports Q4 revenue $13.6M, consensus $13.41M. “The fourth quarter marked a pivotal inflection point for Nurix as we...

9d ago

NRIX

Nurix Therapeutics highlights key objectives, milestones

Nurix Therapeutics (NRIX) highlighted the Company’s achievements in 2025 and outlined key objectives and anticipated milestones for 2026....

26d ago

NRIX

Nurix Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley upgraded Nurix Therapeutics (NRIX) to Overweight from Equal Weight with a price target of $36, up...

30d ago

NRIX

Nurix Therapeutics Exposed to Significant Foreign Exchange Risk Amid Unhedged Currency Exposure

Nurix Therapeutics, Inc. (NRIX) has disclosed a new risk, in the Capital Markets category. Nurix Therapeutics, Inc. faces...

8d ago

NRIX

Nurix Therapeutics, Inc. Reported Earnings. Did it Beat Estimates?

Nurix Therapeutics, Inc. (NRIX) reported an earnings beat for its 4th quarter, ending 11/30/2025. Earnings per share came...

9d ago

NRIX

Nurix Therapeutics Outlines 2026 Goals and Pipeline Progress

Nurix Therapeutics ( ($NRIX) ) has shared an announcement. On January 12, 2026, Nurix Therapeutics presented its 2025...

26d ago

NRIX

Nurix Therapeutics Advances Study for NX-5948 in CLL and SLL Patients

Nurix Therapeutics, Inc. ($NRIX) announced an update on their ongoing clinical study. Study Overview: Nurix Therapeutics, Inc. (NRIX)...

2M ago

NRIX

HOOD, IBTA, IRDM: Cathie Wood Buys the Dip in Robinhood, Sells Ibotta and Iridium Stocks

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) reported several key trades for Thursday, December 11. The prominent hedge fund manager capitalized...

2M ago

ARKF

Cathie Wood Capitalizes the Surge in Iridium and Biotech Stocks

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio adjustments on Wednesday, December 10, as revealed in...

2M ago

TER

ADPT

NRIX FAQ

What was Nurix Therapeutics’s price range in the past 12 months?

Nurix Therapeutics lowest stock price was $8.18 and its highest was $22.50 in the past 12 months.

What is Nurix Therapeutics’s market cap?

Nurix Therapeutics’s market cap is $1.70B.

When is Nurix Therapeutics’s upcoming earnings report date?

Nurix Therapeutics’s upcoming earnings report date is Apr 14, 2026 which is in 66 days.

How were Nurix Therapeutics’s earnings last quarter?

Nurix Therapeutics released its earnings results on Jan 28, 2026. The company reported -$0.82 earnings per share for the quarter, beating the consensus estimate of -$0.871 by $0.051.

Is Nurix Therapeutics overvalued?

According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nurix Therapeutics pay dividends?

Nurix Therapeutics does not currently pay dividends.

What is Nurix Therapeutics’s EPS estimate?

Nurix Therapeutics’s EPS estimate is -0.77.

How many shares outstanding does Nurix Therapeutics have?

Nurix Therapeutics has 102,843,010 shares outstanding.

What happened to Nurix Therapeutics’s price movement after its last earnings report?

Nurix Therapeutics reported an EPS of -$0.82 in its last earnings report, beating expectations of -$0.871. Following the earnings report the stock price went down -1.567%.

Which hedge fund is a major shareholder of Nurix Therapeutics?

Currently, no hedge funds are holding shares in NRIX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Nurix Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-49.63%

Trailing 12-Months

Asset Growth

4.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nurix Therapeutics

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Nurix Therapeutics (NRIX) Earnings & Revenues

Historic Earnings Reports

NRIX Stock 12 Month Forecast

Average Price Target

$30.50

▲(84.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","25":"$25","42":"$42","16.5":"$16.5","33.5":"$33.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$41.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,16.5,25,33.5,42],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.97,20.664615384615384,22.35923076923077,24.053846153846152,25.748461538461537,27.443076923076923,29.137692307692305,30.83230769230769,32.526923076923076,34.22153846153846,35.91615384615385,37.61076923076923,39.30538461538461,{"y":41,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.97,19.856923076923074,20.743846153846153,21.63076923076923,22.517692307692307,23.404615384615383,24.29153846153846,25.178461538461537,26.065384615384616,26.95230769230769,27.839230769230767,28.726153846153846,29.613076923076925,{"y":30.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.97,19.20307692307692,19.436153846153847,19.66923076923077,19.90230769230769,20.135384615384616,20.36846153846154,20.60153846153846,20.834615384615383,21.067692307692308,21.30076923076923,21.533846153846152,21.766923076923078,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.71,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.97,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >